Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could interferon be a hidden trigger of blood clot damage after transplant?

NCT ID NCT07705789

Not yet recruiting Knowledge-focused Sponsor: Sofie Dhaese Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study investigates how interferon and complement proteins contribute to thrombotic microangiopathy (TMA), a serious condition involving small blood clots and organ damage that can occur after stem cell transplants. Researchers will measure interferon levels, complement activity, and VEGF-A in blood and urine samples from 40 adults, including transplant recipients with and without TMA. The goal is to clarify whether interferon, alongside complement, drives the blood vessel damage seen in TMA.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this research could identify interferon as a key driver of TMA, pointing toward new treatment targets for this serious complication.
What could go wrong
This is an observational study with a small sample of 40 people, so findings may not apply broadly and will need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THROMBOTIC MICROANGIOPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thrombotic microangiopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THROMBOTIC MICROANGIOPATHIES

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.